<html><head></head><body><pre style="word-wrap: break-word; white-space: pre-wrap;">// API callback
jQuery111008695687496988914_1514819942086({"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$blogger":"http://schemas.google.com/blogger/2008","xmlns$georss":"http://www.georss.org/georss","xmlns$gd":"http://schemas.google.com/g/2005","xmlns$thr":"http://purl.org/syndication/thread/1.0","id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095"},"updated":{"$t":"2018-01-01T10:18:06.378+05:30"},"category":[{"term":"Latest Updates"},{"term":"Features"},{"term":"USFDA"},{"term":"EMA"},{"term":"Regulatory Affairs News"}],"title":{"type":"text","$t":"PharmaRIIM"},"subtitle":{"type":"html","$t":""},"link":[{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"http:\/\/www.pharmariim.com\/feeds\/posts\/default"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default?alt=json-in-script\u0026max-results=6"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/"},{"rel":"hub","href":"http://pubsubhubbub.appspot.com/"},{"rel":"next","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default?alt=json-in-script\u0026start-index=7\u0026max-results=6"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"generator":{"version":"7.00","uri":"http://www.blogger.com","$t":"Blogger"},"openSearch$totalResults":{"$t":"12"},"openSearch$startIndex":{"$t":"1"},"openSearch$itemsPerPage":{"$t":"6"},"entry":[{"id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095.post-2159719176632758010"},"published":{"$t":"2018-01-01T09:00:00.000+05:30"},"updated":{"$t":"2018-01-01T09:00:01.715+05:30"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Features"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Latest Updates"}],"title":{"type":"text","$t":"Official Launch of PharmaRIIM-January 1st, 2018"},"content":{"type":"html","$t":"\u003Cdiv dir=\"ltr\" style=\"text-align: left;\" trbidi=\"on\"\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cdiv style=\"text-align: center;\"\u003E\u003Cspan style=\"font-size: x-large;\"\u003EWelcome to PharmaRIIM\u003C\/span\u003E\u003C\/div\u003E\u003Cspan style=\"font-size: large;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003Cspan style=\"font-size: large;\"\u003EHi Readers,\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/3.bp.blogspot.com\/-3k5pLWTYmSo\/WkdMts_YCHI\/AAAAAAAAAAs\/cRlRXNH3V_IvVody259QGemf5rzuVvhJACPcBGAYYCw\/s1600\/PharmaRIIM%2BLogo%2BCropped%2Bfor%2BBlogger.jpeg\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg border=\"0\" data-original-height=\"206\" data-original-width=\"720\" height=\"91\" src=\"https:\/\/3.bp.blogspot.com\/-3k5pLWTYmSo\/WkdMts_YCHI\/AAAAAAAAAAs\/cRlRXNH3V_IvVody259QGemf5rzuVvhJACPcBGAYYCw\/s320\/PharmaRIIM%2BLogo%2BCropped%2Bfor%2BBlogger.jpeg\" width=\"320\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cspan style=\"font-size: large;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cspan style=\"font-size: large;\"\u003EWe are posting the latest updates on Pharma Regulatory Affairs and also providing the online live courses to B.Pharm\/M.Pharm Graduates. Please support us, we will create more useful post and it will help to Drug Regualtory Affairs Students and Professionals.\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cspan style=\"font-size: large;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: center;\"\u003E\u003Cspan style=\"font-size: large;\"\u003EWe wish you a Happy New Year 2018\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/4.bp.blogspot.com\/-saRWODA9eeI\/Wki_2WJrY_I\/AAAAAAAAAA8\/En86a_AOnRE6YTk0txbxlLs_3ddKGFFvQCLcBGAs\/s1600\/Happy-New-Year-Images-2018-HD-1-1.jpg\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg border=\"0\" data-original-height=\"750\" data-original-width=\"1000\" height=\"300\" src=\"https:\/\/4.bp.blogspot.com\/-saRWODA9eeI\/Wki_2WJrY_I\/AAAAAAAAAA8\/En86a_AOnRE6YTk0txbxlLs_3ddKGFFvQCLcBGAs\/s400\/Happy-New-Year-Images-2018-HD-1-1.jpg\" width=\"400\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: center;\"\u003E\u003Cspan style=\"font-size: large;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003Cbr \/\u003E\u003Cdiv style=\"text-align: left;\"\u003E\u003Cspan style=\"font-size: large;\"\u003ESubscribe with email and Get Latest Updates.\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: left;\"\u003E\u003Cspan style=\"font-size: large;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: left;\"\u003E\u003Cspan style=\"font-size: large;\"\u003EFrom,\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: left;\"\u003E\u003Cspan style=\"font-size: large;\"\u003EPharmaRIIM\u003C\/span\u003E\u003Cbr \/\u003E\u003Cspan style=\"font-size: large;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E"},"link":[{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/2159719176632758010"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/2159719176632758010"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/2018\/01\/official-launch-of-pharmariim-january.html","title":"Official Launch of PharmaRIIM-January 1st, 2018"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/3.bp.blogspot.com\/-3k5pLWTYmSo\/WkdMts_YCHI\/AAAAAAAAAAs\/cRlRXNH3V_IvVody259QGemf5rzuVvhJACPcBGAYYCw\/s72-c\/PharmaRIIM%2BLogo%2BCropped%2Bfor%2BBlogger.jpeg","height":"72","width":"72"}},{"id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095.post-4427982782869070524"},"published":{"$t":"2017-12-31T17:38:00.000+05:30"},"updated":{"$t":"2017-12-31T22:29:31.304+05:30"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Features"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Latest Updates"}],"title":{"type":"text","$t":"Official Launch on January 1st, 2018"},"content":{"type":"html","$t":"\u003Cdiv dir=\"ltr\" style=\"text-align: left;\" trbidi=\"on\"\u003EDear All,\u003Cbr \/\u003E\u003Cbr \/\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/2.bp.blogspot.com\/-lbY0iLdCDq4\/WkjTEP7MqoI\/AAAAAAAAABk\/I1wA1QbyQu4GUaHdsenrT8C5jBDlUnzQwCLcBGAs\/s1600\/coming%2Bsoon.jpg\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg border=\"0\" data-original-height=\"225\" data-original-width=\"225\" src=\"https:\/\/2.bp.blogspot.com\/-lbY0iLdCDq4\/WkjTEP7MqoI\/AAAAAAAAABk\/I1wA1QbyQu4GUaHdsenrT8C5jBDlUnzQwCLcBGAs\/s1600\/coming%2Bsoon.jpg\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cbr \/\u003EWe will launch this site officially on January 1st, 2018, Thank you all.\u003Cbr \/\u003E\u003Cbr \/\u003EFrom,\u003Cbr \/\u003EPharmarRIIM.\u003C\/div\u003E"},"link":[{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/4427982782869070524"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/4427982782869070524"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/official-launch-on-january-1st-2018.html","title":"Official Launch on January 1st, 2018"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/2.bp.blogspot.com\/-lbY0iLdCDq4\/WkjTEP7MqoI\/AAAAAAAAABk\/I1wA1QbyQu4GUaHdsenrT8C5jBDlUnzQwCLcBGAs\/s72-c\/coming%2Bsoon.jpg","height":"72","width":"72"}},{"id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095.post-8526617923248192593"},"published":{"$t":"2017-12-31T16:48:00.002+05:30"},"updated":{"$t":"2017-12-31T17:31:09.758+05:30"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Features"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Latest Updates"}],"title":{"type":"text","$t":"Generic drugs"},"content":{"type":"html","$t":"\u003Cdiv dir=\"ltr\" style=\"text-align: left;\" trbidi=\"on\"\u003E\u003Cdiv style=\"background-color: white; margin-bottom: 6px;\"\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/4.bp.blogspot.com\/-UW-F30mteqc\/WkjHaFXk5EI\/AAAAAAAAABM\/eOAVL4JaVZIBtld4goIoQo6yGM4GgYaEACLcBGAs\/s1600\/generic.jpg\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg alt=\"\" border=\"0\" data-original-height=\"160\" data-original-width=\"240\" height=\"133\" src=\"https:\/\/4.bp.blogspot.com\/-UW-F30mteqc\/WkjHaFXk5EI\/AAAAAAAAABM\/eOAVL4JaVZIBtld4goIoQo6yGM4GgYaEACLcBGAs\/s200\/generic.jpg\" title=\"Generic-drugs\" width=\"200\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cspan style=\"font-family: inherit;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003Cspan style=\"font-family: inherit;\"\u003EGeneric drugs are copies of innovator or brand-name prescription drugs and make up about 88 percent of prescriptions filled in the United States. Brand-name drugs must demonstrate their safety and effectiveness through expensive and time-consuming research and development programs, including clinical studies.\u0026nbsp;\u003C\/span\u003E\u003Cbr \/\u003E\u003Cspan style=\"font-family: inherit;\"\u003E\u003Cspan style=\"color: #073763; font-family: \u0026quot;georgia\u0026quot; , \u0026quot;times new roman\u0026quot; , serif;\"\u003E\u003C\/span\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003Cspan style=\"font-family: inherit;\"\u003E\u003Ca href=\"https:\/\/www.blogger.com\/null\" name=\"more\"\u003E\u003C\/a\u003E\u003Cspan style=\"color: #073763; font-family: \u0026quot;georgia\u0026quot; , \u0026quot;times new roman\u0026quot; , serif;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003Cspan style=\"color: #073763; font-family: \u0026quot;georgia\u0026quot; , \u0026quot;times new roman\u0026quot; , serif;\"\u003EIn contrast, generic drug developers can use data from their brand-name counterparts, resulting in much less expensive development programs and affordable\u003Cspan class=\"text_exposed_show\" style=\"display: inline;\"\u003E\u0026nbsp;access to treatments for many patients and consumers.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\"text_exposed_show\" style=\"background-color: white; display: inline;\"\u003E\u003Cdiv style=\"margin-bottom: 6px;\"\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cspan style=\"font-family: inherit;\"\u003EFDA requires a generic drug company produce enough data to demonstrate it can make a drug that can be appropriately substituted for its brand-name counterpart. The challenge to the generic drug maker is to prove to FDA that the generic version is substitutable with a brand-name drug that has been shown to be safe and effective. FDA’s challenge is to carefully review that data to ensure it proves the same thing.\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E"},"link":[{"rel":"replies","type":"application/atom+xml","href":"http:\/\/www.pharmariim.com\/feeds\/8526617923248192593\/comments\/default","title":"Post Comments"},{"rel":"replies","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/generic-drugs.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/8526617923248192593"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/8526617923248192593"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/generic-drugs.html","title":"Generic drugs"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/4.bp.blogspot.com\/-UW-F30mteqc\/WkjHaFXk5EI\/AAAAAAAAABM\/eOAVL4JaVZIBtld4goIoQo6yGM4GgYaEACLcBGAs\/s72-c\/generic.jpg","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095.post-2235843521055918966"},"published":{"$t":"2017-12-27T11:50:00.000+05:30"},"updated":{"$t":"2017-12-31T16:32:41.988+05:30"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Features"},{"scheme":"http://www.blogger.com/atom/ns#","term":"USFDA"}],"title":{"type":"text","$t":"The Orange Book"},"content":{"type":"html","$t":"\u003Cdiv dir=\"ltr\" style=\"text-align: left;\" trbidi=\"on\"\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/4.bp.blogspot.com\/-rTncpmQLvKk\/WkM8GvjpGzI\/AAAAAAAAAJc\/iQEVm_wjcjEjnUjLwOAlc_1BavHWyBsLwCLcBGAs\/s1600\/orange%2Bbook.jpeg\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg alt=\"\" border=\"0\" data-original-height=\"183\" data-original-width=\"275\" height=\"132\" src=\"https:\/\/4.bp.blogspot.com\/-rTncpmQLvKk\/WkM8GvjpGzI\/AAAAAAAAAJc\/iQEVm_wjcjEjnUjLwOAlc_1BavHWyBsLwCLcBGAs\/s200\/orange%2Bbook.jpeg\" title=\"The USFDA Orange Book\" width=\"200\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cspan style=\"background-color: white; font-family: \u0026quot;helvetica neue\u0026quot; , \u0026quot;helvetica\u0026quot; , \u0026quot;arial\u0026quot; , sans-serif;\"\u003E\u003Cbr \/\u003E\u003C\/span\u003E\u003Cdiv class=\"MsoNormal\"\u003E\u003Cspan style=\"background: white; font-family: \u0026quot;arial\u0026quot; , sans-serif; line-height: 115%;\"\u003EThe publication\u0026nbsp;Approved Drug Products with Therapeutic Equivalence Evaluations\u0026nbsp;(commonly known as the Orange Book) identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act) and related patent and exclusivity information.\u003C\/span\u003E\u003Co:p\u003E\u003C\/o:p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Ca href=\"https:\/\/www.blogger.com\/null\" name=\"more\"\u003E\u003C\/a\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003Cstrong style=\"box-sizing: border-box;\"\u003E\u003Cspan style=\"background-color: white; font-weight: 400;\"\u003EThe Orange Book is composed of four parts:\u0026nbsp;\u003C\/span\u003E\u003C\/strong\u003E\u003C\/strong\u003E\u003C\/div\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003Cstrong style=\"box-sizing: border-box;\"\u003E\u003Cspan style=\"background-color: white; font-weight: 400;\"\u003E(1) approved prescription drug products with therapeutic equivalence evaluations;\u0026nbsp;\u003C\/span\u003E\u003C\/strong\u003E\u003C\/strong\u003E\u003C\/div\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003Cstrong style=\"box-sizing: border-box;\"\u003E\u003Cspan style=\"background-color: white; font-weight: 400;\"\u003E(2) approved over‑the‑counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs;\u0026nbsp;\u003C\/span\u003E\u003C\/strong\u003E\u003C\/strong\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003Cstrong style=\"box-sizing: border-box;\"\u003E\u003Cspan style=\"background-color: white; font-weight: 400;\"\u003E(3) drug products with approval under Section 505 of the FD\u0026amp;C Act administered by the Center for Biologics Evaluation and Research; and\u0026nbsp;\u003C\/span\u003E\u003C\/strong\u003E\u003C\/strong\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003Cstrong style=\"box-sizing: border-box;\"\u003E\u003Cspan style=\"background-color: white; font-weight: 400;\"\u003E(4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.\u003C\/span\u003E\u003C\/strong\u003E\u003C\/strong\u003E\u003C\/div\u003E\u003Cbr \/\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cbr \/\u003E\u003C\/div\u003E\u003Cdiv style=\"text-align: justify;\"\u003E\u003Cstrong style=\"box-sizing: border-box; font-family: \u0026quot;Helvetica Neue\u0026quot;, Helvetica, Arial, sans-serif; text-align: start;\"\u003E\u003Ca href=\"http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/default.cfm\" style=\"border-bottom: 1px dotted; box-sizing: border-box; text-decoration-line: none;\" target=\"_blank\"\u003ESearch the Orange Book Database\u003C\/a\u003E\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cspan style=\"background-color: #d9edf7; font-family: \u0026quot;helvetica neue\u0026quot; , \u0026quot;helvetica\u0026quot; , \u0026quot;arial\u0026quot; , sans-serif;\"\u003ESearch approved drug products by active ingredient, proprietary name, applicant, application number, dosage form, route of administration or patent number.\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E"},"link":[{"rel":"replies","type":"application/atom+xml","href":"http:\/\/www.pharmariim.com\/feeds\/2235843521055918966\/comments\/default","title":"Post Comments"},{"rel":"replies","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/the-orange-book.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/2235843521055918966"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/2235843521055918966"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/the-orange-book.html","title":"The Orange Book"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/4.bp.blogspot.com\/-rTncpmQLvKk\/WkM8GvjpGzI\/AAAAAAAAAJc\/iQEVm_wjcjEjnUjLwOAlc_1BavHWyBsLwCLcBGAs\/s72-c\/orange%2Bbook.jpeg","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095.post-5584143745679890244"},"published":{"$t":"2017-12-26T09:46:00.000+05:30"},"updated":{"$t":"2017-12-31T22:30:05.091+05:30"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Latest Updates"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Regulatory Affairs News"},{"scheme":"http://www.blogger.com/atom/ns#","term":"USFDA"}],"title":{"type":"text","$t":" FDA Draft Guidance on CMC Changes for Biologics"},"content":{"type":"html","$t":"\u003Cdiv dir=\"ltr\" style=\"text-align: left;\" trbidi=\"on\"\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/1.bp.blogspot.com\/-y_Sf7R5ZkFg\/WkHJvzwqMSI\/AAAAAAAAAIU\/OBUyCO4D18kmAM2q3Jewoh8RRiAsdlFJwCEwYBhgL\/s1600\/FDA.png\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg alt=\"\" border=\"0\" data-original-height=\"195\" data-original-width=\"260\" height=\"147\" src=\"https:\/\/1.bp.blogspot.com\/-y_Sf7R5ZkFg\/WkHJvzwqMSI\/AAAAAAAAAIU\/OBUyCO4D18kmAM2q3Jewoh8RRiAsdlFJwCEwYBhgL\/s200\/FDA.png\" title=\"FDA Draft Guidance on CMC Changes for Biologics\" width=\"200\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: left; text-rendering: optimizeLegibility;\"\u003EThe US Food and Drug Administration (FDA) on Thursday released draft guidance intended to help applicants and manufacturers of certain licensed biological products in determining which reporting category is appropriate for a change in chemistry, manufacturing, and controls (CMC) information to an approved biologics license application (BLA).\u003C\/div\u003E\u003Ca href=\"https:\/\/www.blogger.com\/null\" name=\"more\"\u003E\u003C\/a\u003E\u003Cbr \/\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: left; text-rendering: optimizeLegibility;\"\u003EBased on a tiered-reporting system for specific changes, the 43-page draft provides applicants and manufacturers with general and administrative information on reporting and evaluating changes and recommendations for reporting categories.\u0026nbsp;\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: left; text-rendering: optimizeLegibility;\"\u003EWhen finalized, the guidance is intended to supersede the document: \"Guidance for Industry: Changes to an Approved Application: Biological Products\" from July 1997.\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: left; text-rendering: optimizeLegibility;\"\u003E\"We are updating the July 1997 guidance to accommodate advances in manufacturing and testing technology and to clarify the FDA’s current thinking on assessing reportable changes,\" FDA\u0026nbsp;\u003Ca href=\"https:\/\/s3.amazonaws.com\/public-inspection.federalregister.gov\/2017-27589.pdf\" style=\"background: transparent; box-sizing: border-box; line-height: inherit; margin: 0px; text-decoration-line: none;\"\u003Esaid in Thursday’s Federal Register\u003C\/a\u003E. \"The updated guidance applies to certain biological products licensed under the\u0026nbsp;\u003Cem style=\"box-sizing: border-box; line-height: inherit; margin: 0px;\"\u003EPublic Health Service Act\u003C\/em\u003E\u0026nbsp;(PHS Act), including in vitro diagnostics licensed under BLAs,\" though it does not apply to human cells, tissues, and cellular and tissue-based products; specified biotechnology and specified synthetic biological products; and biosimilar biological products subject to licensure under section 351(k) of the PHS Act.\u003C\/div\u003E\u003C\/div\u003E"},"link":[{"rel":"replies","type":"application/atom+xml","href":"http:\/\/www.pharmariim.com\/feeds\/5584143745679890244\/comments\/default","title":"Post Comments"},{"rel":"replies","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/fda-draft-guidance-on-cmc-changes-for.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/5584143745679890244"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/5584143745679890244"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/fda-draft-guidance-on-cmc-changes-for.html","title":" FDA Draft Guidance on CMC Changes for Biologics"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/1.bp.blogspot.com\/-y_Sf7R5ZkFg\/WkHJvzwqMSI\/AAAAAAAAAIU\/OBUyCO4D18kmAM2q3Jewoh8RRiAsdlFJwCEwYBhgL\/s72-c\/FDA.png","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-2661023182102645095.post-6437526361591546590"},"published":{"$t":"2017-12-26T09:42:00.000+05:30"},"updated":{"$t":"2017-12-31T16:38:22.432+05:30"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"EMA"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Latest Updates"}],"title":{"type":"text","$t":"EMA: Pharmacovigilance Fees to Rise in 2018"},"content":{"type":"html","$t":"\u003Cdiv dir=\"ltr\" style=\"text-align: left;\" trbidi=\"on\"\u003E\u003Cdiv class=\"separator\" style=\"clear: both; text-align: center;\"\u003E\u003Ca href=\"https:\/\/4.bp.blogspot.com\/-k6_QK7tHeao\/WiVaw-tyoLI\/AAAAAAAAADQ\/wtPByEBhpUoL_IUdM2xhkXAWxr53eNz6ACPcBGAYYCw\/s1600\/ema.png\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"\u003E\u003Cimg alt=\"\" border=\"0\" data-original-height=\"155\" data-original-width=\"324\" height=\"95\" src=\"https:\/\/4.bp.blogspot.com\/-k6_QK7tHeao\/WiVaw-tyoLI\/AAAAAAAAADQ\/wtPByEBhpUoL_IUdM2xhkXAWxr53eNz6ACPcBGAYYCw\/s200\/ema.png\" title=\"EMA: Pharmacovigilance Fees to Rise in 2018\" width=\"200\" \/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003E\u003Cbr \/\u003E\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003EThe European Medicines Agency (EMA) on Wednesday said it expects fees paid by drugmakers for pharmacovigilance applications to rise by 1.4% in mid-January 2018.\u003C\/div\u003E\u003Ca href=\"https:\/\/www.blogger.com\/null\" name=\"more\"\u003E\u003C\/a\u003E\u003Cbr \/\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003EPharmacovigilance fees in in the EU are set by\u0026nbsp;\u003Ca href=\"https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/reg_2014_658\/reg_2014_658_en.pdf\" style=\"background: transparent; box-sizing: border-box; line-height: inherit; margin: 0px; text-decoration-line: none;\"\u003E\u003Cem style=\"box-sizing: border-box; line-height: inherit; margin: 0px;\"\u003ERegulation (EU) No 658\/2014\u003C\/em\u003E\u003C\/a\u003E, which includes provisions for the European Commission to adjust the fees to keep up with the rate of inflation as measured by the European Index of Consumer prices.\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003EDue to a low level of inflation in 2015 (0.2%), the Commission in 2016 said that a fee increase was not justified for 2017.\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003EBut in a\u0026nbsp;\u003Ca href=\"http:\/\/ec.europa.eu\/transparency\/regdoc\/rep\/3\/2017\/EN\/C-2017-6946-F1-EN-MAIN-PART-1.PDF\" style=\"background: transparent; box-sizing: border-box; line-height: inherit; margin: 0px; text-decoration-line: none;\"\u003Edelegated regulation\u003C\/a\u003E\u0026nbsp;adopted in October, the Commission said it would increase pharmacovigilance fees beginning in 2018 to account for the combined inflation rate in 2015 and 2016.\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003E\"In view of the inflation rate for 2016, (1.2%) it is considered justified to proceed to such adjustment and to apply a cumulative adjustment taking into account both 2015 and 2016 inflation rates,\" the Commission said.\u003C\/div\u003E\u003Cdiv style=\"background-color: white; box-sizing: border-box; direction: ltr; font-family: Helvetica, sans-serif; line-height: 1.6; margin-bottom: 1.25rem; padding: 0px; text-align: justify; text-rendering: optimizeLegibility;\"\u003EAs such, EMA said it expects the fees to climb by 1.4% and plans to release full details on the adjusted fees in January once the regulation is published in the\u0026nbsp;\u003Cem style=\"box-sizing: border-box; line-height: inherit; margin: 0px;\"\u003EOfficial Journal of the European Union\u003C\/em\u003E.\u003C\/div\u003E\u003C\/div\u003E"},"link":[{"rel":"replies","type":"application/atom+xml","href":"http:\/\/www.pharmariim.com\/feeds\/6437526361591546590\/comments\/default","title":"Post Comments"},{"rel":"replies","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/ema-pharmacovigilance-fees-to-rise-in.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/6437526361591546590"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/2661023182102645095\/posts\/default\/6437526361591546590"},{"rel":"alternate","type":"text/html","href":"http:\/\/www.pharmariim.com\/2017\/12\/ema-pharmacovigilance-fees-to-rise-in.html","title":"EMA: Pharmacovigilance Fees to Rise in 2018"}],"author":[{"name":{"$t":"PharmaRIIM"},"uri":{"$t":"http:\/\/www.blogger.com\/profile\/09479238619137525820"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"16","height":"16","src":"https:\/\/img1.blogblog.com\/img\/b16-rounded.gif"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/4.bp.blogspot.com\/-k6_QK7tHeao\/WiVaw-tyoLI\/AAAAAAAAADQ\/wtPByEBhpUoL_IUdM2xhkXAWxr53eNz6ACPcBGAYYCw\/s72-c\/ema.png","height":"72","width":"72"},"thr$total":{"$t":"0"}}]}});</pre></body></html>